FIELD: pharmaceutics.
SUBSTANCE: invention relates to an agent improving anti-cancer effect of another antitumour agent containing 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide and another antitumour agent, which is selected from a group consisting of paclitaxel, gemcitabine, lapatinib, tegafur-gimeracil-oteracil potassium combination drug and irinotecan. Invention also relates to an antitumour agent based on said components, use of said quinoline carboxamide derivative and a method of treating a tumour, based on use of agent consisting of said quinoline carboxamide derivative and other antitumour agent.
EFFECT: technical result is development of an agent enhancing antitumour effect of another antitumour agent.
6 cl, 9 dwg, 6 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTITUMOR EFFECT AMPLIFYER CONTAINING IMIDAZOOXAAZINE COMPOUND | 2013 |
|
RU2618423C2 |
| DRUG AND COMPOSITION FOR TREATMENT OF MALIGNANT TUMORS | 2017 |
|
RU2777595C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
| COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
| COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
| ANTITUMOR AGENT AND ANTITUMOR EFFECT AMPLIFIER | 2018 |
|
RU2783759C2 |
| ANTITUMOR AGENT, ANTITUMOR ENHANCER AND ANTITUMOR KIT | 2017 |
|
RU2752172C2 |
| NEW DERIVATIVES OF PEG | 2015 |
|
RU2697551C2 |
| PHARMACEUTICAL COMBINATION FOR CANCER TREATMENT | 2018 |
|
RU2801665C2 |
